Literature DB >> 16192855

Retrospective study of 18 patients treated by maxillomandibular advancement with adjunctive procedures for obstructive sleep apnea syndrome.

Y Smatt1, J Ferri.   

Abstract

A surgical protocol in the treatment of obstructive sleep apnea syndrome (OSAS) is presented. Eighteen patients with particular craniofacial characteristics consisting in maxillomandibular retroposition or retromandibulism underwent bimaxillary advancement by way of Lefort I and bilateral sagittal ramus osteotomies. Adjunctive procedures (genioplasty, uvuloplasty, and glossoplasty) were performed in the same surgical procedure. In all cases, the patients were evaluated before and 6 months after surgery by a physical examination, Delaire cephalometric analysis, and polysomnography. Surgery was considered successful when the postoperative apnea/hypopnea index (AHI) was less than 15/h and with at least a 50% reduction of the initial index. The surgical success rate was 84%. AHI decreased from 54/h (+/-20.7) to 9.66/h (+/-6.67). The results of this study indicate that successful surgical treatment by maxillomandibular advancement with adjunctive procedures at the same operative time is efficient with a high percentage of success when patients are clearly selected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192855     DOI: 10.1097/01.scs.0000179746.98789.0f

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  10 in total

1.  Volumetric analysis of the pharynx in patients with obstructive sleep apnea (OSA) treated with maxillomandibular advancement (MMA).

Authors:  Ana Célia Faria; Savio Nogueira da Silva-Junior; Luis Vicente Garcia; Antonio Carlos dos Santos; Maria Regina França Fernandes; Francisco Veríssimo de Mello-Filho
Journal:  Sleep Breath       Date:  2012-05-06       Impact factor: 2.816

2.  LeFort I Osteotomy.

Authors:  Edward P Buchanan; Charles H Hyman
Journal:  Semin Plast Surg       Date:  2013-08       Impact factor: 2.314

3.  Skeletal stability of patients undergoing maxillomandibular advancement for treatment of obstructive sleep apnea.

Authors:  Sang Hwa Lee; Leonard B Kaban; Edward T Lahey
Journal:  J Oral Maxillofac Surg       Date:  2014-10-29       Impact factor: 1.895

4.  Efficacy and safety of maxillomandibular advancement in treatment of obstructive sleep apnoea syndrome.

Authors:  M Giarda; M Brucoli; F Arcuri; R Benech; A Braghiroli; A Benech
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-02       Impact factor: 2.124

5.  [Surgical management of obstructive sleep apnea].

Authors:  P Kessler; F Ruberg; H Obbarius; H Iro; F W Neukam
Journal:  Mund Kiefer Gesichtschir       Date:  2007-04

6.  Epigenetic influence of KAT6B and HDAC4 in the development of skeletal malocclusion.

Authors:  Ahrin Huh; Michael J Horton; Karen T Cuenco; Gwenael Raoul; Anthea M Rowlerson; Joel Ferri; James J Sciote
Journal:  Am J Orthod Dentofacial Orthop       Date:  2013-10       Impact factor: 2.650

7.  Maxillomandibular advancement for obstructive sleep apnea: a retrospective prognostic factor study for surgical response.

Authors:  Ning Zhou; Jean-Pierre T F Ho; Wouter P Visscher; Naichuan Su; Frank Lobbezoo; Jan de Lange
Journal:  Sleep Breath       Date:  2022-10-22       Impact factor: 2.655

8.  Contemporary surgery for obstructive sleep apnea syndrome.

Authors:  Nelson B Powell
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-09-23       Impact factor: 3.372

9.  Bimaxillary advancement as the initial treatment of obstructive sleep apnea: five years follow-up of the pori experience.

Authors:  Antti Raunio; Esa Rauhala; Minna Kiviharju; Ossi Lehmijoki; George K B Sándor; Kyösti Oikarinen
Journal:  J Oral Maxillofac Res       Date:  2012-04-01

10.  Impact of Bimaxillary Advancement Surgery on the Upper Airway and on Obstructive Sleep Apnea Syndrome: a Meta-Analysis.

Authors:  Carolina Rojo-Sanchis; José Manuel Almerich-Silla; Vanessa Paredes-Gallardo; José María Montiel-Company; Carlos Bellot-Arcís
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.